Navigation Links
Mayo Clinic study finds apathy and depression predict progression from mild cognitive impairment

ROCHESTER, Minn. -- A new Mayo Clinic study found that apathy and depression significantly predict an individual's progression from mild cognitive impairment (MCI), a disorder of the brain that affects nerve cells involved in thinking abilities, to dementia, including Alzheimer's disease and Lewy body dementia. The study was presented at the International Conference on Alzheimer's Disease in Honolulu on July 11, 2010.

"An important area of study is the identification of biomarkers and clinical predictors for the progression from normal cognition to mild cognitive impairment and mild cognitive impairment to dementia," says Yonas E. Geda, M.D., a Mayo Clinic neuropsychiatrist and the study's lead investigator. "We knew from previous smaller studies that neuropsychiatric symptoms like depression, apathy and agitation seem to predict progression from mild cognitive impairment to dementia, so we set out to look at this hypothesis in a population-based setting with a larger sample size."

Depression and apathy are neuropsychiatric symptoms that are often difficult to distinguish, according to Dr. Geda. Depression causes changes in mood, thinking, physical well-being and behavior, while apathy is loss of motivation without associated feelings of being depressed or blue.

As part of the Mayo Clinic Study of Aging, Dr. Geda and a team of Mayo Clinic researchers identified 358 individuals with mild cognitive impairment and used a questionnaire to collect data on depression and apathy. Then, they prospectively followed individuals to the outcome of dementia (a median of 2.8 years). Among 87 individuals with depression, 30 (34.5 percent) developed dementia. Of the 271 individuals without depression, 59 (21.8 percent) developed dementia. Among 60 individuals with apathy, 22 (36.7 percent) developed dementia. Of the 298 individuals without apathy, 67 (22.5 percent) developed dementia.

After adjusting for age, gender and education, the researchers found that the individuals with mild cognitive impairment and depression had a 66 percent increased risk of developing dementia than those individuals with mild cognitive impairment without depression. Likewise, the individuals with mild cognitive impairment and apathy had a 99 percent increased risk of developing dementia than those individuals with mild cognitive impairment without apathy.

"These findings highlight the importance of thoroughly evaluating newly-diagnosed patients with mild cognitive impairment for neuropsychiatric symptoms. The next step is to conduct a study to find out if treatment of depression or apathy in MCI may delay the onset of dementia," says Dr. Geda. "This delay could have a huge impact on the quality of life for individual patients and their families, not to mention the broad public health implications of delaying the societal and economic burden of dementia. In fact, a previous biostatistics study from our colleagues at Johns Hopkins indicated that delaying dementia by a mere one year could reduce the prevalence of Alzheimer's disease by nearly 800,000 million fewer cases in 2050."


Contact: Elizabeth Rice
Mayo Clinic

Related medicine news :

1. The West Clinic Joins Cancer Clinics of Excellence (CCE)
2. Stethoscope App gives iPhone New Clinical Skills
3. Mayo Clinic responsible for $22 billion in economic impact, including $9.6 billion in Minnesota
4. Sunquest Introduces Integrated Clinical Environment Physician Portal Solution in US
5. Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials
6. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
7. Sunquest Completes System-Wide Implementation at Cleveland Clinic Hospital Laboratories
8. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
9. NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland
10. UCLA Health System Presents: How to Successfully Implement a Clinical Portal
11. International Merchant Advisors CEO Mel Roseman to Discuss New Medical Marijuana Clinics Live on CBS Radio Networks Big Biz Show February 22, 2010 at 1:40 pm PST
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 02, 2015 , ... Ruth Pearson ... brutal lupus flare-up. Unable to walk without assistance and quickly losing hope of recovering ... then a miracle happened. , Pearson was attending a women’s retreat when she experienced ...
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition ... funds for Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday ... from patients including their ability to work and be productive, to do simple daily ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Royal River Natural ... new study that found post-menopausal women who took the nutritional supplement creatine, along with ... who trained but did not take creatine. , The report is part of the ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... leadless pacemakers in the U.S. and is the only hospital in the region ... largest clinical data presentation of transcatheter pacing patients were revealed recently at a ...
(Date:12/1/2015)... ... 01, 2015 , ... December 1, 2015 -- InstantLabs is ... growing product line of food safety and seafood fraud prevention tools. , The ... allow InstantLabs to offer fast, reliable species identification for the four most popular ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Russia has always been a ... new drugs registered in Europe in 2015 were ... Russia has always been a country of choice ... in Europe in 2015 were tested in phase ... Russia has always been a country of choice for global ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... 1, 2015  The migration to value-based care ... care plans that help patients stay healthy and ... be digitally enabled, incorporate care guidelines and be ... They will also allow all stakeholders to collaborate ... is optimal. That is the vision, however, research ...
Breaking Medicine Technology: